Comparison Overview

SpringWorks Therapeutics

VS

Amgen

SpringWorks Therapeutics

100 Washington Blvd, Stamford, Connecticut, 06902, US
Last Update: 2025-03-05 (UTC)
View Profile
Between 750 and 799
http://www.springworkstx.com

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 388
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Amgen

One Amgen Center Drive, Thousand Oaks, CA, 91320, US
Last Update: 2025-05-06 (UTC)
Between 800 and 849
http://www.amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 37,835
Subsidiaries: 4
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/amgen.jpeg
Amgen
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
SpringWorks Therapeutics
100%
Compliance Rate
0/4 Standards Verified
Amgen
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for SpringWorks Therapeutics in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Amgen in 2025.

Incident History — SpringWorks Therapeutics (X = Date, Y = Severity)

SpringWorks Therapeutics cyber incidents detection timeline including parent company and subsidiaries

Incident History — Amgen (X = Date, Y = Severity)

Amgen cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
Incidents

No Incident

https://images.rankiteo.com/companyimages/amgen.jpeg
Amgen
Incidents

Date Detected: 4/2021
Type:Breach
Attack Vector: Compromised Service Account
Blog: Blog

FAQ

Amgen company demonstrates a stronger AI Cybersecurity Score compared to SpringWorks Therapeutics company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Amgen company has historically faced a number of disclosed cyber incidents, whereas SpringWorks Therapeutics company has not reported any.

In the current year, Amgen company and SpringWorks Therapeutics company have not reported any cyber incidents.

Neither Amgen company nor SpringWorks Therapeutics company has reported experiencing a ransomware attack publicly.

Amgen company has disclosed at least one data breach, while SpringWorks Therapeutics company has not reported such incidents publicly.

Neither Amgen company nor SpringWorks Therapeutics company has reported experiencing targeted cyberattacks publicly.

Neither SpringWorks Therapeutics company nor Amgen company has reported experiencing or disclosing vulnerabilities publicly.

Neither SpringWorks Therapeutics nor Amgen holds any compliance certifications.

Neither company holds any compliance certifications.

Amgen company has more subsidiaries worldwide compared to SpringWorks Therapeutics company.

Amgen company employs more people globally than SpringWorks Therapeutics company, reflecting its scale as a Biotechnology Research.

Neither SpringWorks Therapeutics nor Amgen holds SOC 2 Type 1 certification.

Neither SpringWorks Therapeutics nor Amgen holds SOC 2 Type 2 certification.

Neither SpringWorks Therapeutics nor Amgen holds ISO 27001 certification.

Neither SpringWorks Therapeutics nor Amgen holds PCI DSS certification.

Neither SpringWorks Therapeutics nor Amgen holds HIPAA certification.

Neither SpringWorks Therapeutics nor Amgen holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References